GlassScriptPhysician profile
Fernando Temporal Mariz
NPI 1043619273
$5,307.46
in general payments reported to CMS, 2019-2025
39 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $461 · 2021: $1,369 · 2022: $1,673 · 2023: $865 · 2024: $494 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.67 |
| Education | $267.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.49 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $626.88 | 2020-2023 | Xifaxan |
| Myovant Sciences INC. | $373.21 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $356.60 | 2021-2025 | |
| Evofem Biosciences, INC. | $333.11 | 2021-2023 | Phexxi |
| Astellas Pharma US INC | $285.97 | 2023-2024 | Veozah |
| Aspira Women'S Health INC | $247.47 | 2022 | |
| Sumitomo Pharma America, INC. | $241.39 | 2023-2024 | Myfembree |
| Therapeuticsmd, INC. | $194.42 | 2020-2022 | |
| Lilly USA, LLC | $146.62 | 2024 | Zepbound |
| Coopersurgical, INC. | $134.12 | 2019-2022 | |
| Novo Nordisk INC | $129.08 | 2021 | |
| Axsome Therapeutics, INC. | $125.24 | 2025 | Auvelity |
| Gilead Sciences, INC. | $119.26 | 2020 | |
| Idorsia Pharmaceuticals US INC | $102.77 | 2023 | Quviviq |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $95.08 | 2019-2021 | |
| Qol Medical, LLC | $92.87 | 2021-2022 | |
| Agile Therapeutics, INC. | $88.38 | 2021-2023 | Twirla |
| Avion Pharmaceuticals | $81.70 | 2019-2021 | |
| Redhill Biopharma INC. | $72.72 | 2020-2022 | |
| Pfizer INC. | $69.57 | 2022-2024 | |
| Exeltis, USA INC. | $68.08 | 2021-2023 | Slynd |
| Viiv Healthcare Company | $56.13 | 2022-2024 | Apretude |
| Merck Sharp & Dohme LLC | $55.43 | 2019-2024 | Gardasil 9, Gardasil |
| Scynexis, INC. | $41.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.27 | 2021 | |
| Janssen Biotech, INC. | $34.22 | 2023 | Stelara |
| Amgen INC. | $33.82 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.13 | 2023 | Dupixent |
| Ardelyx, INC. | $25.97 | 2023 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $24.65 | 2021 | |
| Daiichi Sankyo INC. | $21.39 | 2020 | |
| Hologic Sales and Service, LLC | $20.91 | 2021 | |
| Organon LLC | $19.19 | 2022 | |
| Phadia US INC. | $19.01 | 2021 | |
| Genentech USA, INC. | $15.91 | 2021 | |
| Kaleo, INC. | $14.79 | 2022 | |
| Alfasigma USA, INC. | $13.88 | 2021 | |
| Currax Pharmaceuticals LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Mariz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.